HENDERA
831152
Hengerda New Materials
300946
Fujian Nebula Electronics.,Ltd
300648
4
Cubic Digital Technology
300344
5
HNAC Technology
300490
US Stock MarketDetailed Quotes
BIOA BioAge Labs
- 4.550
- -0.240-5.01%
Trading Feb 18 11:14 ET
163.11MMarket Cap-2.19P/E (TTM)
4.800High4.530Low86.17KVolume4.800Open4.790Pre Close403.45KTurnover0.82%Turnover RatioLossP/E (Static)35.85MShares26.62052wk High0.52P/B47.78MFloat Cap3.85052wk Low--Dividend TTM10.50MShs Float26.620Historical High--Div YieldTTM5.64%Amplitude3.850Historical Low4.681Avg Price1Lot Size
BioAge Labs Stock Forum
Sign in to post a comment
$BioAge Labs (BIOA.US)$
Milestone Achievement: Alzheimer's Breakthrough Leqembi Reaches €200M Sales, Triggering Major Payout
Milestone Achievement: Alzheimer's Breakthrough Leqembi Reaches €200M Sales, Triggering Major Payout
1
The attention of AI Medteck stocks are rapidly increasing.
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
106
12
268
$BioAge Labs (BIOA.US)$ no volume
$BioAge Labs (BIOA.US)$ this one dead
$BioAge Labs (BIOA.US)$ Dead. No more hope
$BioAge Labs (BIOA.US)$
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
Tuesday, 28th January at 9:00 am
Advancement of next-generation APJ agonists with discontinuation of azelaprag
Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025
Expansion of discovery efforts based on insights from BioAge's platform, including a target identification collaboration with Novartis and a newly announced antibo...
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
Tuesday, 28th January at 9:00 am
Advancement of next-generation APJ agonists with discontinuation of azelaprag
Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025
Expansion of discovery efforts based on insights from BioAge's platform, including a target identification collaboration with Novartis and a newly announced antibo...
2
1
$BioAge Labs (BIOA.US)$ this stock is dead
$BioAge Labs (BIOA.US)$ No volume
$BioAge Labs (BIOA.US)$ institution is accumulating so just be patience
1
$BioAge Labs (BIOA.US)$ super slow and no volume
No comment yet
Trending Stocks
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Moo Live
Feb 12 16:30
Alibaba Group Q4 FY2024 earnings conference call
Fortune Smiles 88 : what has to do with BIOA?